Osteoporosis Therapy — SCE Endocrinology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Planned zoledronate infusion at six months with CTX-guided follow-up
C is correct. Denosumab must not be stopped or delayed without an antiresorptive exit plan. NOGG recommends zoledronate 5 mg IV six months after the last denosumab injection, with serum CTX guiding further treatment; if CTX is unavailable, a further zoledronate dose six months later can be considered. A drug holiday, delayed rescue or progressively prolonged dosing permits rebound turnover. Teriparatide alone after denosumab can worsen transient bone loss.
Reference: https://www.nogg.org.uk/full-guideline/section-6-pharmacological-treatment-options